EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection – Epidemiology Forecast to 2022

Publisher Name :
Date: 15-Nov-2013
No. of pages: 54

Urinary tract infections (UTIs) are among the most common bacterial infections acquired in hospitals and in the community setting. A UTI can occur when daily living activities and medical interventions aid in the movement of bacteria into the urethra; however, bacterial colonization does not always lead to the development of UTI symptoms. Although UTIs can be caused by bacteria, viruses, or fungi, gram-negative bacteria are the pathogens most frequently associated with UTIs. Gram-negative bacteria have become increasingly resistant to individual antimicrobials, and of particular concern, is the emergence of multidrug-resistant activity in these organisms. Although there has been little change in the predominant causative pathogens in the past few decades, individual pathogen frequency and resistance patterns of gram-negative pathogens vary considerably between settings, countries, and continents.

According to GlobalData’s forecast, the number of incident cases of UTI will increase in the US during the forecast period. The largest number of cases will be classified as community-acquired and occur in women =80 years of age. The 5EU will see a slight increase in the number of healthcare-associated incident cases of UTI during the forecast period, with the highest number of cases occurring among women in Germany, and among those ages 70-79 years. Japan is forecast to see a large increase in the number of incident cases of UTI occurring during the forecast period in intensive care units, with the greatest number of cases occurring among women and those =80 years.

A major strength of this analysis is that GlobalData epidemiologists used country-specific sources for each market in the analysis and were able to obtain country-specific national surveillance data for the 5EU and Japan. The use of country-specific sources is especially important for antimicrobial resistance data as the rates of resistance have been found to vary considerably between countries. Additionally, because resistance rates have changed over time, GlobalData’s use of recent sources for resistance rates ensures that the estimates for the number of resistant cases of UTI reflect the most current situation in each market.

Scope

  • The Gram-Negative Bacterial Urinary Tract Infection (UTI) EpiCast Report provides an overview of the risk factors and global trends of UTI in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of UTI incident cases segmented by age (0-85 years and older), sex, causative pathogen (Escherichia coli, Klebsiella, Pseudomonas aeruginosa, Proteus, and Acinetobacter), multidrug resistance, and carbapenem resistance in these markets.
  • The UTI epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global UTI market.
  • Quantify patient populations in the global UTI market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex, age groups, pathogens, and antibiotic resistance patterns that present the best opportunities for UTI therapeutics in each of the markets covered.

EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection – Epidemiology Forecast to 2022

Table Of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8

3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.2.1 Women are more likely than men to experience UTI at all ages 11
3.2.2 The risk of developing UTI increases 3%-6% per day of catheterization 11
3.2.3 Older age is a major risk factor for UTI 12
3.2.4 Sexual intercourse can increase the relative odds of UTI in women by a factor as high as 60 13
3.2.5 Diabetic individuals have an increased incidence of UTI and increased associated complications 13
3.3 Forecast Methodology 14
3.3.1 Sources Used 15
3.3.2 Forecast Assumptions and Methods 19
3.4 Epidemiological Forecast for UTI (2012-2022) 24
3.4.1 US 24
3.4.2 5EU 29
3.4.3 Japan 36
3.5 Discussion 41
3.5.1 Conclusions on Epidemiological Trends 41
3.5.2 Limitations of the Analysis 42
3.5.3 Strengths of the Analysis 43

4 Appendix 44
4.1 Bibliography 44
4.2 About the Authors 49
4.2.1 Epidemiologists 49
4.2.2 Reviewers 49
4.2.3 Franka des Vignes, PhD, Global Director of Epidemiology and Health Policy 51
4.2.4 Bonnie Bain, PhD, Global Head of Healthcare 51
4.3 About GlobalData 52
4.4 About EpiCast 52
4.5 Disclaimer 53

List of Tables

Table 1: Risk Factors for Urinary Tract Infection 11
Table 2: Sources of Incidence Data Used in the Epidemiology Forecast 14
Table 3: US, Incident Cases of Gram-Negative UTI, N, by Site of Acquisition, Select Years, 2012-2022 25
Table 4: US, Incident Cases of Gram-Negative UTI, by Age and Site of Acquisition, N (Row %), 2012 26
Table 5: US, Incident Cases of Gram-Negative UTI, by Sex and Site of Acquisition, N (Row %), 2012 27
Table 6: US, Incident Cases of Gram-Negative UTI, by Pathogen and Site of Acquisition, N (Column %), 2012 28
Table 7: US, Incident Cases of Gram-Negative UTI, by Pathogen and Multidrug* and Carbapenem† Resistance, N, Percentage of Pathogen-Specific Cases, 2012 29
Table 8: 5EU, Incident Cases of UTI, N, Select Years, 2012-2022 30
Table 9: 5EU, Incident Cases of UTI, by Age, N (Row %), 2012 31
Table 10: 5EU, Incident Cases of UTI, by Sex, N (Row %), 2012 32
Table 11: 5EU, Incident Cases of UTI, by Pathogen, N (Percentage of Total Country-Specific Cases Caused by Pathogen), 2012 33
Table 12: 5EU, Incident Cases of UTI, by Pathogen and Multidrug and Carbapenem Resistance, N, and Percentage of Pathogen-Specific Cases, 2012 35
Table 13: Japan, Incident Cases of UTI, N, Select Years, 2012-2022 36
Table 14: Japan, Incident Cases of UTI, by Age, N (Row %), 2012 37
Table 15: Japan, Incident Cases of UTI, by Sex, N (Row %), 2012 38
Table 16: Japan, Incident Cases of UTI, by Pathogen, N (Percentage of Total Country-Specific Cases Caused by Pathogen), 2012 39
Table 17: Japan, Incident Cases of UTI, by Pathogen and Antibiotic, Number of Antibiotic-Resistant Cases (N) and Percentage of Antibiotic-Resistant Pathogen-Specific Cases (%), 2012 40

List of Figures

Figure 1: US, Incident Cases of Gram-Negative UTI, N, by Site of Acquisition, Select Years, 2012-2022 25
Figure 2: US, Incident Cases of Gram-Negative UTI, by Age and Site of Acquisition, N, 2012 26
Figure 3: US, Incident Cases of Gram-Negative UTI, by Sex, N, 2012 27
Figure 4: US, Incident Cases of Gram-Negative UTI, by Pathogen and Site of Acquisition, N, 2012 28
Figure 5: 5EU, Incident Cases of UTI, N, Select Years, 2012-2022 30
Figure 6: 5EU, Incident Cases of UTI, by Age, N, 2012 31
Figure 7: 5EU, Incident Cases of UTI, by Sex, N, 2012 32
Figure 8: 5EU, Incident Cases of UTI, by Pathogen, N, 2012 34
Figure 9: Japan, Incident Cases of UTI, N, Select Years, 2012-2022 36
Figure 10: Japan, Incident Cases of UTI, by Age, N, 2012 37
Figure 11: Japan, Incident Cases of UTI, by Sex, N, 2012 38
Figure 12: Japan, Incident Cases of UTI, by Pathogen, N, 2012 39

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 – New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options
    Published: 29-Oct-2014        Price: US $4995 Onwards        
    GBI Research, a leading business intelligence provider, has released its latest research report: “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options”, which provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan......
  • Cell Expansion Market by Product (Reagent, Media, Serum, Bioreactors, Centrifuge), Cell Type (human, animal), Application (Stem Cell Research, Regenerative Medicine, Clinical Diagnostics), End User (Hospital, Biotechnology, Cell Bank) – Forecast to 2019
    Published: 29-Oct-2014        Price: US $4650 Onwards        Pages: 224
    The global cell expansion market is expected to reach $14.8 billion by 2019 from $6.0 billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019. The global cell expansion market is categorized on the basis of product, cell type, application, end user, and geography. The human cell expansion segment is expected to register the highest growth rate in the cell expansion market, by cell type, during the forecast period. Its favorable growth is attributed to increasing focus on human stem cell re......
  • Aortic Stent Grafts – Current and Future Players
    Published: 29-Oct-2014        Price: US $3500 Onwards        Pages: 106
    Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient’s native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated r......
  • Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma
    Published: 29-Oct-2014        Price: US $6995 Onwards        
    Large Degree of Innovation in NSCLC Pipeline The NSCLC pipeline currently has 389 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market comprises primarily ineffective chemotherapies that target tubulin or DNA replication, the pipeline shows an incredibly diverse range of therapies targeting multiple signaling pathways and molecules integral to cancer development. Thi......
  • Global Biologic Therapeutics Market 2014-2018
    Published: 29-Oct-2014        Price: US $3500 Onwards        Pages: 185
    Biologic therapeutics include virus, therapeutic serum, toxin, allergenic product, antitoxin, blood component or derivative, vaccine, blood, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), intended for the prevention, treatment, or cure of a disease or condition. These products differ from small molecules in terms of molecular weight, structure, synthesis, and immunogen......
  • Egypt Pharmaceuticals and Healthcare Report Q4 2014
    Published: 29-Oct-2014        Price: US $1295 Onwards        Pages: 126
    BMI View: Egypt's relative political stability will lead to a pickup in growth over the coming quarters, increasing the attractiveness of the pharmaceutical market - for which our forecast has been revised slightly upwards. The government's increased emphasis on developing the pharmaceutical sector and the announced expansion of the Medicare healthcare programme are positive developments this quarter. The challenges faced by pharmaceutical companies wishing to operate in the market are the c......
  • Global Pharmaceutical Packaging Market 2014-2018
    Published: 29-Oct-2014        Price: US $2500 Onwards        Pages: 77
    A pharmaceutical product is any chemical substance formulated or compounded as a single active ingredient. The packaging of medicines is a very complex process, and because of its molecular and chemical structure, it needs to be packed in an extremely durable material so that it could reach the customer in a desirable condition. The evolution of new diseases and increased health awareness have brought a transformation in the Pharmaceutical Packaging market. The vendors in the Global Pharmaceutic......
  • Indonesia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 29-Oct-2014        Price: US $1295 Onwards        Pages: 142
    BMI View: Indonesia is one of the most promising markets for the pharmaceutical and healthcare companies in South East Asia. The country's large population, positive economic outlook and considerable disease burden bode well for growth in demand for drugs, medical devices and healthcare services. The ongoing implementation of the universal healthcare scheme in Indonesia coupled with the impending launch of the ASEAN Economic Community will provide growth opportunities for pharmaceutical firm......
  • Global Polymerase Chain Reaction (PCR) Market 2014-2018
    Published: 29-Oct-2014        Price: US $2500 Onwards        Pages: 75
    Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short pe......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs